V enous thromboembolism (VTE) is a common and potentially life-threatening medical condition. The National Quality Forum reports that VTE is the third most common cause of hospital-associated deaths in the United States and the most common preventable cause of hospital death. 31 In addition, VTE remains the second most common cause of increased length of stay (LOS), and third most common cause of excess charges. 31 The Agency for Healthcare Research and Quality lists postoperative VTE as 1 of the 20 patient-safety indicators (see http://www.qualityindicators. ahrq.gov/modules/psi_resources.aspx), and the Center for Medicare and Medicaid Services lists VTE as a potential "hospital-acquired condition" that can affect hospital ratings and reimbursement.
bidities known to potentially increase VTE occurrence, such as polytrauma or cancer. 18, 19 The incidence of VTE after spine surgery is poorly defined and highly variable, with published rates ranging from 0.3% to 31%. 6, [9] [10] [11] 28, 32, 35 This high variance is likely due to heterogeneities of the studied patient populations as well as to inconsistent treatment practices and diagnostic measures.
Prophylaxis for VTE consists of mechanical and chemical modalities, and studies have demonstrated that multimodal therapy is most beneficial. 7, 21 While it is generally accepted that mechanical prophylaxis with compression stocking (CS) or sequential compression devices (SCDs) after spine surgery is both effective and safe, 12, 20, 25 the same is not universally accepted for chemoprophylaxis with anticoagulation therapy. Anticoagulation therapy is known to reduce thrombotic events; 7, 8, 21 however, the safety and timing of initiating chemoprophylaxis postoperatively remains controversial. 4, 15 The concern with early anticoagulation chemoprophylaxis is the potential risk for bleeding complications, specifically, acute postoperative formation of EDH with significant neurological sequelae.
Unfortunately, little evidence exists in the literature to guide management specifically for patients undergoing spine surgery. The American College of Chest Physicians 20, 21, 25 and the North American Spine Society 4 have published guidelines for VTE prevention, but neither provides universal or specific recommendations on which to base treatment decisions. As a result, the Department of Neurosurgery at the University of Florida implemented a standardized VTE-prophylaxis protocol for all patients undergoing spine surgery at this institution. The protocol provides a specific treatment algorithm that combines mechanical prophylaxis with SCDs and early initiation of anticoagulation chemoprophylaxis on hospital admission (whether before or at the time of surgery). The purpose of the present study was to compare the safety and efficacy of this aggressive multimodal VTE-prophylaxis protocol with those of nonstandardized management.
Methods
Before implementation of the protocol (that is, prior to 2008), VTE prophylaxis was determined by the individual provider on a case-by-case basis and was generally less aggressive with regards to timing or extent of chemoprophylaxis. In early 2008, the Department of Neurosurgery at the University of Florida established a multidisciplinary task force aimed at developing an aggressive VTE-prophylaxis protocol for all spine surgery patients. The task force included neurosurgeons, hematologists, critical-care specialists, and pharmacists. Its goal was to establish an evidence-based protocol that could be applied to all patients undergoing neurosurgery of the spine. An extensive literature review was conducted. Additional factors, such as cost and clinical feasibility, were also considered. After several months of collaborative work, the "Adult Venous Thromboembolism Prophylaxis Order Form" was developed (Fig. 1) . It was approved by the Departments of Neurosurgery and Hematology at the University of Florida, Shands Hospital, and implemented in the spring of 2008.
The VTE-prophylaxis protocol involves chemoprophylaxis for all patients with any spinal disorder at the time of admission, whether preoperatively (if the patient was admitted before surgery) or immediately postoperatively (if the patient was admitted on the day of surgery). Patients are given 5000 units heparin subcutaneously 3 times daily, except those older than 75 years or weighing less than 50 kg, who receive dosing twice daily (Fig. 1) . All patients are fitted with SCDs for mechanical prophylaxis.
In an effort to determine the relative efficacy and safety of this standardized protocol for early multimodal prophylaxis in spine surgery patients, an institutional review board-approved retrospective review of outcomes in patients 2 years before protocol implementation ( icd-9-code-lookup.aspx). Adverse events due to chemoprophylaxis were defined as occurrence of a postoperative hematoma in the surgical area requiring operative evacuation. Patients who underwent postoperative EDH evacuation were identified by the Current Procedural Terminology (CPT) coding modifier 78. This modifier is used for "unplanned return to the operating room by the same physician following initial procedure for a related procedure during the postoperative period." 1 A chart review was performed by the authors on all cases with modifier 78 to identify those specifically related to postoperative EDH, or any other complication involving bleeding that required a return to the operating room.
Statistics
To statistically evaluate differences in the distributions of patient demographics between the pre-and postprotocol groups, we used the t-test (age) and chi-square test (sex and race). For patients who had multiple procedures, we included only the first procedure in the analysis. To evaluate the differences in the distributions of risk factors, diagnoses, LOS, and procedures and outcomes between the groups, we included all procedures and used generalized estimating equations to compare the groups, taking each variable as the dependent variable and preor postprotocol as the independent variable. We assumed either binomial or normal distributions for the dependent variable, and we included patient as a repeated factor. We used generalized estimating equations also to evaluate the effect of time period (pre-or postprotocol) on the development of DVT when controlling for obesity, trauma, history of DVT, cancer, limited mobility, and tobacco use. We assumed a binomial distribution for DVT (yes or no), were performed using the SAS statistical software package (version 9.3).
Results
In this study, 1933 patients met the inclusion criteria: 941 spine surgery patients in the group before the implementation of the VTE-prophylaxis protocol (preprotocol group) and 992 after its implementation (postprotocol group). Table 1 shows the general demographics for each group. Comparisons of the risk factors, diagnoses, LOSs, procedures, and outcomes are listed in Table 2 . Of the patients in the preprotocol group, 25 had a DVT (2.7%), 6 a PE (0.6%), and 6 an EDH (0.6%) postoperatively. Of those in the postprotocol group, 10 had a DVT (1.0%), 5 a PE (0.5%), and 4 an EDH (0.4%) postoperatively. The reduction in DVTs after implementation of the VTE-prophylaxis protocol was statistically significant (p = 0.009; Table 2 ). No statistically significant differences were detected between the 2 groups in the rates of PE (p = 0.767) and EDH (p = 0.583). Detailed descriptions of patients who had a postoperative EDH are given in Table 3 . No inpatient died because of DVT or PE in either group.
Rates of DVT with our prophylaxis protocol were significantly lower than published DVT rates with no prophylaxis (p = 0.001), CS alone (p = 0.016), and SCDs alone (p < 0.001) ( Table 4) . Differences between the DVT rates in our study and those in published reports using combination therapy with or without chemoprophylaxis were not statistically significant (p = 0.289). Rates of postoperative EDH before and after protocol implementation (0.6% and 0.4%, respectively) in our study were also not statistically significantly different (p = 0.538). In the literature, published rates of postoperative EDH are slightly higher with chemoprophylaxis (0.314%) than without chemoprophylaxis (0.180%), 16 and this difference was statistically significant (p = 0.021). However, no significant differences were detected between the rate of postoperative EDH with our VTE-prophylaxis protocol and previously published rates of postoperative EDH with (p = 0.770) or without (p = 0.135) chemoprophylaxis.
Discussion
According to the National Quality Forum, VTE is the cause of death of 300,000 people in the United States each year. 31 A relatively frequent hospital-acquired condition, VTE is a common cause of morbidity and death. Spinal disorders, in particular, increase the risk for developing VTE because of multiple factors originating from both the underlying disease and associated comorbidities. Impaired mobility due to preexisting disability, pain, or neurological weakness leads to increased venous stasis. Comorbidities such as obesity and smoking further increase this risk. 18 Certain spinal conditions are associated with particularly high rates of DVT, whether due to associated malignancy, polytrauma, or spinal cord injury (DJ Hoh, D Neal, and BL Hoh, presentation at the AANS/ CNS Joint Section on Disorders of the Spine and Peripheral Nerves Annual Meeting, 2013). 24, 30, 40 Multiple randomized clinical trials have shown that mechanical prophylaxis and chemoprophylaxis are effective for reducing VTE rates for various nonspinal conditions. 7, 8, 19, 20 Currently, there is little evidence to guide preventive management in patients with spinal damage or disease, particularly in those undergoing surgery. A 2009 survey by Glotzbecker et al. reported that a consensus regarding VTE prophylaxis is lacking among spine surgeons. 15 This lack of consensus is reflected by large variability in management across a wide range of institutions and providers, particularly with respect to postoperative anticoagulation, and recent publications have highlighted the need for better guidelines. 3, 22 Despite the known efficacy of chemoprophylaxis, Glotzbecker et al. reported that surveys asking when postoperative anticoagulation was initiated showed a wide range of responses, from 72 hours (13%), 48 hours (22%), 24 hours (15%), and immediately after surgery (12%). 15 This variation in chemoprophylaxis presumably stems from concerns that anticoagulation therapy starting early after surgery may result in bleeding complications.
To address these issues, our department developed a standardized VTE-prophylaxis protocol designed to reduce DVTs and PEs with early multimodal mechanical and chemoprophylaxis. Specifically, in addition to SCDs, the protocol involves initiating anticoagulation therapy preoperatively for those patients admitted before surgery, or immediately postoperatively for those who are admitted on the day of surgery. Further, anticoagulation dosing with heparin was standardized to 3 times daily (for adults younger than 75 years and weighing more than 50 kg) to align treatment with recommendations from the American College of Chest Physicians for general VTE prophylaxis. 20, 21, 25 The objective of this protocol was to prevent VTE with aggressive early intervention, without increasing the risk of adverse events, such as anticoagulation-associated bleeding complications. The protocol was implemented in 2008 and was assessed for safety and efficacy by comparing its outcomes to those among patients treated at our department before the protocol's implementation. In these patients, VTE prophylaxis had been widely variable because preprotocol management was nonstandardized and decided on a case-by-case basis, with chemoprophylaxis commonly delayed until >24 hours postoperation. In addition, preprotocol anticoagulation therapy frequently involved lower heparin doses (that is, twice daily dosing) than those recommended for effective VTE prophylaxis by the most recent guidelines of the American College of Chest Physicians.
20,21,25
The demographics of the 941 patients in the preprotocol group were relatively well matched with those of the 992 patients in the postprotocol group in terms of age, sex, and race. The patients in the 2 groups were also relativity well matched for primary diagnosis and procedures, and both groups had a similar LOS. Although the p value for the difference in average between the 2 groups (52.5 years in the preprotocol group vs 54.5 years in the postprotocol group) indicated a statistically significant difference in age between the groups, it is not likely that this differ- ence was clinically significant. Among the patients in the postprotocol group, a higher proportion had risks factors commonly thought to contribute to VTE, such as obesity and a history of VTE. After controlling for obesity, trauma, limited mobility, prior history of DVT, smoking, and cancer, we estimated that the patients in the postprotocol group had 0.28 times the odds (that is, a 72% lower risk) of developing DVT than patients in the preprotocol group (95% CI 0.122-0.665, p = 0.0037). This decreased risk for developing DVT in the postprotocol group supports the idea that the protocol's implementation and not the variability in patient demographics or risk factors was the reason for the improvement in treatment outcomes.
We observed a significant reduction in the DVT rate from 2.7% in the preprotocol group to 1.0% in the postprotocol group. This lowered rate of DVT after protocol implementation compares favorably to those reported previously in the literature when evaluated with statistical models.
9-11,14,17,32-35,37 However, we did not observe a corresponding statistically significant reduction in the PE rate with our protocol. This lack of statistical significance was likely due to the fact that the number of PEs was overall lower than the number of DVTs. If the difference in the rate of PE between the pre-and postprotocol groups is indeed only 0.14 percentage points, then more than 90,000 subjects would be required to have a sufficiently powered study to detect any statistical significance of such a difference.
An explanation for the overall low PE rate is the relatively common practice of filter placement in the inferior vena cava in high-risk patients with symptomatic DVT.
In this study, we did not include the placement of inferior vena cava filters as a covariant. This is a clear limitation of our study, and it is possible that changes in filter placement could affect the PE results. Nevertheless, with respect to DVT (which is not affected by the filter placement), we did observe a statistically significant improvement after protocol implementation.
The increased efficacy of the VTE-prophylaxis protocol for reducing VTE was not offset by an increased risk of postoperative complications arising from bleeding. Symptomatic EDH formation, defined as requiring surgical evacuation, was rare both before (0.6%) and after (0.4%) protocol implementation. A symptomatic postoperative EDH incidence of less than 4 per 1000 patients with aggressive early VTE prophylaxis compares favorably to previously reported rates of 0.2%-1%. 5, 14, 16, 26, 29, 38, 41 Using statistical modeling, we found that the occurrence of postoperative EDH after protocol implementation was similar to the existing literature (p = 0.770), indicating the overall safety of immediate anticoagulation chemoprophylaxis.
There are several limitations, however, to this study. A randomized controlled trial comparing the outcomes of this protocol of early multimodal VTE prophylaxis with those of no protocol would strengthen the quality of the evidence. The overall low incidence of DVT and PE with some form of prophylaxis, however, would likely render a randomized controlled trial unfeasible, given the number of individuals necessary to adequately power such a study. Moreover, a truly placebo-controlled trial (that is, one that would withhold both mechanical and chemopro- 16 † DVT rates were 2.7% in the preprotocol group and 1.0% in the postprotocol group; PE rates were 0.6% in the preprotocol group and 0.5% in the postprotocol group; and EDH rates were 0.6% in the preprotocol group and 0.4% in the postprotocol group. J Neurosurg: Spine / Volume 21 / October 2014 phylaxis for the control group) would be unethical, given the known benefits of these interventions for reducing potentially significant VTE-associated morbidity and mortality rates.
The reliance on ICD-9 codes for identifying DVT and PE may have resulted in potential errors in reporting, 42 because only VTEs diagnosed during hospitalization were recorded. A recent study, however, comparing the use of ICD-9 codes versus medical extraction for the identification of postoperative DVT and PE revealed that medical extraction is more likely to underreport VTEs. Conversely, relying on ICD-9 codes may falsely elevate rates of VTEs. 23 Therefore, the true incidences of DVT and PE (whether before or after protocol implementation) may be lower than those we observed. The use of ICD-9 codes to identify complications in large data sets is still being validated, and therefore limits the drawing of conclusions from the data. 36, 39 In addition, patients in this study were not routinely screened for DVT with surveillance ultrasonography. A study in which neurosurgery patients underwent weekly venous duplex ultrasonography of the lower extremities reported a high rate (2.8%) of DVTs. 4 It is our institutional practice that patients undergo diagnostic imaging only if they show symptoms or if there is clinical basis to suspect possible DVT or PE. Therefore, it is quite possible that DVT or PE rates may have been actually higher than reported here, although one may argue that "silent" VTEs may not be clinically relevant or not necessitate additional intervention.
Perhaps the most significant potential limitation of this study was the method of assessing adverse events. Early anticoagulation therapy elevates the risk of increased bleeding, particularly of hematoma formation at the surgical site. Epidural hematoma after spine surgery can lead to neurological damage, necessitating urgent return to the operating room for hematoma evacuation. We likely captured most patients with a symptomatic EDH by cross-matching the spine surgery patients in either study group who also had a listed CPT code for EDH evacuation within 90 days after their index procedure. It is possible that after anticoagulation treatment a percentage of patients developed a postoperative EDH that was not symptomatic or did not necessitate intervention, although one may argue that such occurrence may not be clinically relevant.
Some patients may have developed a symptomatic EDH after discharge from our institution and may have been treated at another institution or been lost to followup. Given the tertiary referral nature of our institution, however, it is unlikely that patients initially treated at our institution subsequently underwent further spine surgical care at another hospital. Moreover, the occurrence of chemoprophylaxis-associated bleeding complications after hospital discharge is likely to be low as anticoagulation was only given in the inpatient setting (except for patients with a known DVT or PE).
We did not assess other bleeding complications besides EDH. Acute blood loss anemia requiring blood transfusion and gastric bleeding are 2 potential complications associated with anticoagulation chemoprophylaxis that were not included in this study. Although mortality rates were also not assessed in patients in this study, we noted that none of the patients who had a DVT, PE, or EDH died during inpatient hospitalization. As further data are collected with continued use of this standardized protocol, a better understanding of these other potential adverse events will be gained.
Conclusions
There continues to be little consensus regarding appropriate VTE prophylaxis after spine surgery. Implementation of an aggressive multimodal VTE-prophylaxis protocol with early initiation of anticoagulation significantly decreased overall VTE rates, especially the development of DVT. Optimal heparin dosing immediately postoperatively also did not result in increased symptomatic EDH, indicating that this heparin-dosing regimen is safe for use in spine surgery patients. 
